Effects of Different Inhalation Therapy on Ventilator-Associated Pneumonia in Ventilated COVID-19 Patients: A Randomized Controlled Trial
Nikola Delić, Andrija Matetic, Josipa Domjanović, Toni Kljaković-Gašpić, Lenko Šarić, Darko Ilić, Svjetlana Došenović, Josipa Domazet, Ruben Kovač, Frane Runjić, Sanda Stojanović Stipić, Božidar Duplančić
Microorganisms, doi:10.3390/microorganisms10061118
The effect of routine inhalation therapy on ventilator-associated pneumonia (VAP) in mechanically ventilated patients with the coronavirus disease (COVID-19) has not been well-defined. This randomized controlled trial included 175 eligible adult patients with COVID-19 who were treated with mechanical ventilation at the University Hospital of Split between October 2020 and June 2021. Patients were randomized and allocated to a control group (no routine inhalation) or one of the treatment arms (inhalation of N-acetylcysteine; 5% saline solution; or 8.4% sodium bicarbonate). The primary outcome was the incidence of VAP, while secondary outcomes included all-cause mortality. Routine inhalation therapy had no effect on the incidence of bacterial or fungal VAP nor on all-cause mortality (p > 0.05). Secondary analyses revealed a significant reduction of Gram-positive and methicillin-resistant Staphylococcus aureus (MRSA) VAP in the treatment groups. Specifically, the bicarbonate group had a statistically significantly lower incidence of Gram-positive bacterial VAP (4.8%), followed by the N-acetylcysteine group (10.3%), 5% saline group (19.0%), and control group (34.6%; p = 0.001). This difference was driven by a lower incidence of MRSA VAP in the bicarbonate group (2.4%), followed by the N-acetylcysteine group (7.7%), 5% saline group (14.3%), and control group (34.6%; p < 0.001). Longer duration of ventilator therapy was the only significant, independent predictor of any bacterial or fungal VAP in the multivariate analysis (aOR 1.14, 95% CI 1.01-1.29, p = 0.038 and aOR 1.05, 95% CI 1.01-1.10, p = 0.028, respectively). In conclusion, inhalation therapy had no effect on the overall VAP incidence or all-cause mortality. Further studies should explore the secondary findings of this study such as the reduction of Gram-positive or MRSA-caused VAP in treated patients.
Conflicts of Interest: The authors declare no conflict of interest.
References
Almand, Moore, Jaykus, Virus-Bacteria Interactions: An Emerging Topic in Human Infection, Viruses,
doi:10.3390/v9030058Bennett, Henderson, Donaldson, Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic Fibrosis, Ann. Am. Thorac. Soc
Bergsson, Reeves, Mcnally, Chotirmall, Greene et al., LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline, J. Immunol,
doi:10.4049/jimmunol.0803959Blonz, Kouatchet, Chudeau, Pontis, Lorber et al., Epidemiology and microbiology of ventilator-associated pneumonia in COVID-19 patients: A multicenter retrospective study in 188 patients in an un-inundated French region, Crit. Care,
doi:10.1186/s13054-021-03493-wChang, Elhusseiny, Yeh, Sun, COVID-19 ICU and mechanical ventilation patient characteristics and outcomes-A systematic review and meta-analysis, PLoS ONE,
doi:10.1371/journal.pone.0246318Cooper, Quinton, Ballard, Mucociliary transport in porcine trachea: Differential effects of inhibiting chloride and bicarbonate secretion, Am. J. Physiol. Lung Cell. Mol. Physiol,
doi:10.1152/ajplung.00143.2012Donaldson, Bennett, Zeman, Knowles, Tarran et al., Mucus Clearance and Lung Function in Cystic Fibrosis with Hypertonic Saline, N. Engl. J. Med,
doi:10.1056/NEJMoa043891Everard, Hind, Ugonna, Freeman, Bradburn et al., SABRE: A multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis, Thorax,
doi:10.1136/thoraxjnl-2014-205953Fumagalli, Panigada, Klompas, Berra, Ventilator-associated pneumonia among SARS-CoV-2 acute respiratory distress syndrome patients, Curr. Opin. Crit. Care,
doi:10.1097/MCC.0000000000000908Giacobbe, Battaglini, Enrile, Dentone, Vena et al., Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study, J. Clin. Med,
doi:10.3390/jcm10040555Gomez, Parazzi, Clinckspoor, Mauch, Pessine et al., Tolerability, and Effects of Sodium Bicarbonate Inhalation in Cystic Fibrosis, Clin. Drug Investig,
doi:10.1007/s40261-019-00861-xHelms, Tacquard, Severac, Leonard-Lorant, Ohana et al., High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study, Intensive Care Med,
doi:10.1007/s00134-020-06062-xIcard, Rubio, The role of mucoactive agents in the mechanically ventilated patient: A review of the literature, Expert Rev. Respir. Med,
doi:10.1080/17476348.2017.1359090Ippolito, Misseri, Catalisano, Marino, Ingoglia et al., Ventilator-Associated Pneumonia in Patients with COVID-19: A Systematic Review and Meta-Analysis, Antibiotics,
doi:10.3390/antibiotics10050545King, Dasgupta, Tomkiewicz, Brown, Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I, Am. J. Respir. Crit. Care Med,
doi:10.1164/ajrccm.156.1.9512074Luyt, Sahnoun, Gautier, Vidal, Burrel et al., Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: A retrospective cohort study, Ann. Intensive Care,
doi:10.1186/s13613-020-00775-4Maes, Higginson, Pereira-Dias, Curran, Parmar et al., Ventilator-associated pneumonia in critically ill patients with COVID-19, Crit. Care,
doi:10.1186/s13054-021-03460-5Masoompour, Anushiravani, Tafaroj Norouz, Evaluation of the Effect of Nebulized N-Acetylcysteine on Respiratory Secretions in Mechanically Ventilated Patients: Randomized Clinical Trial, Iran. J. Med. Sci
Mccullers, The co-pathogenesis of influenza viruses with bacteria in the lung, Nat. Rev. Microbiol,
doi:10.1038/nrmicro3231Melsen, Rovers, Koeman, Bonten, Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies, Crit. Care Med,
doi:10.1097/CCM.0b013e3182281f33Michon, Jumas-Bilak, Chiron, Lamy, Marchandin, Advances toward the elucidation of hypertonic saline effects on Pseudomonas aeruginosa from cystic fibrosis patients, PLoS ONE,
doi:10.1371/journal.pone.0090164Moretti, Van Laethem, Minini, Pierard, Malbrain, Ventilator-associated bacterial pneumonia in coronavirus 2019 disease, a retrospective monocentric cohort study, J. Infect. Chemother,
doi:10.1016/j.jiac.2021.01.011Máiz Carro, Martínez-García, Nebulized hypertonic saline in noncystic fibrosis bronchiectasis: A comprehensive review, Ther. Adv. Respir. Dis,
doi:10.1177/1753466619866102Pickens, Gao, Cuttica, Smith, Pesce et al., Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia, Am. J. Respir. Crit. Care Med,
doi:10.1164/rccm.202106-1354OCQu, Ren, Guo, Liang, Xu et al., ffect of N-acetylcysteine inhalation on ventilator-associated pneumonia caused by biofilm in endotracheal tubes, Zhonghua Er Ke Za Zhi
Ranieri, Rubenfeld, Thompson, Ferguson, Caldwell et al., Acute Respiratory Distress Syndrome: The Berlin Definition, JAMA
Rawson, Moore, Zhu, Ranganathan, Skolimowska et al., Bacterial and Fungal Coinfection in Individuals with Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing, Clin. Infect. Dis,
doi:10.1093/cid/ciaa530Razazi, Arrestier, Haudebourg, Benelli, Carteaux et al., Correction to: Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease, Crit. Care,
doi:10.1186/s13054-021-03517-5Robinson, Hemming, Regnis, Wong, Bailey et al., Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis, Thorax,
doi:10.1136/thx.52.10.900Rogers, Mucoactive agents for airway mucus hypersecretory diseases, Respir. Care
Rouyer, Strazzulla, Youbong, Tarteret, Pitsch et al., Ventilator-Associated Pneumonia in COVID-19 Patients: A Retrospective Cohort Study, Antibiotics,
doi:10.3390/antibiotics10080988Rouzé, Martin-Loeches, Povoa, Makris, Artigas et al., Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: A European multicenter cohort study, Intensive Care Med,
doi:10.1007/s00134-020-06323-9Stigliani, Manniello, Zegarra-Moran, Galietta, Minicucci et al., Rheological Properties of Cystic Fibrosis Bronchial Secretion and in Vitro Drug Permeation Study: The Effect of Sodium Bicarbonate, J. Aerosol Med. Pulm. Drug Deliv,
doi:10.1089/jamp.2015.1228Van Meenen, Van Der Hoeven, Binnekade, De Borgie, Merkus et al., Effect of On-Demand vs Routine Nebulization of Acetylcysteine with Salbutamol on Ventilator-Free Days in Intensive Care Unit Patients Receiving Invasive Ventilation: A Randomized Clinical Trial, JAMA,
doi:10.1001/jama.2018.0949Wardeh, Conklin, Ko, Case reports of observed significant improvement in patients with ARDS due to COVID-19 and maximum ventilatory support after inhalation of sodium bicarbonate, J. Clin. Intensive Care Med,
doi:10.29328/journal.jcicm.1001029Wicky, Niedermann, Timsit, Ventilator-associated pneumonia in the era of COVID-19 pandemic: How common and what is the impact?, Crit. Care,
doi:10.1186/s13054-021-03571-zWills, Hall, Chan, Cole, Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea, J. Clin. Investig,
doi:10.1172/JCI119138Wu, Mcgoogan, Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention, JAMA,
doi:10.1001/jama.2020.2648Zhang, Mendoza-Sassi, Wainwright, Klassen, Nebulised hypertonic saline solution for acute bronchiolitis in infants, Cochrane Database Syst. Rev,
doi:10.1002/14651858.CD006458.pub3DOI record:
{
"DOI": "10.3390/microorganisms10061118",
"ISSN": [
"2076-2607"
],
"URL": "http://dx.doi.org/10.3390/microorganisms10061118",
"abstract": "<jats:p>The effect of routine inhalation therapy on ventilator-associated pneumonia (VAP) in mechanically ventilated patients with the coronavirus disease (COVID-19) has not been well-defined. This randomized controlled trial included 175 eligible adult patients with COVID-19 who were treated with mechanical ventilation at the University Hospital of Split between October 2020 and June 2021. Patients were randomized and allocated to a control group (no routine inhalation) or one of the treatment arms (inhalation of N-acetylcysteine; 5% saline solution; or 8.4% sodium bicarbonate). The primary outcome was the incidence of VAP, while secondary outcomes included all-cause mortality. Routine inhalation therapy had no effect on the incidence of bacterial or fungal VAP nor on all-cause mortality (p > 0.05). Secondary analyses revealed a significant reduction of Gram-positive and methicillin-resistant Staphylococcus aureus (MRSA) VAP in the treatment groups. Specifically, the bicarbonate group had a statistically significantly lower incidence of Gram-positive bacterial VAP (4.8%), followed by the N-acetylcysteine group (10.3%), 5% saline group (19.0%), and control group (34.6%; p = 0.001). This difference was driven by a lower incidence of MRSA VAP in the bicarbonate group (2.4%), followed by the N-acetylcysteine group (7.7%), 5% saline group (14.3%), and control group (34.6%; p < 0.001). Longer duration of ventilator therapy was the only significant, independent predictor of any bacterial or fungal VAP in the multivariate analysis (aOR 1.14, 95% CI 1.01–1.29, p = 0.038 and aOR 1.05, 95% CI 1.01–1.10, p = 0.028, respectively). In conclusion, inhalation therapy had no effect on the overall VAP incidence or all-cause mortality. Further studies should explore the secondary findings of this study such as the reduction of Gram-positive or MRSA-caused VAP in treated patients.</jats:p>",
"alternative-id": [
"microorganisms10061118"
],
"author": [
{
"affiliation": [],
"family": "Delić",
"given": "Nikola",
"sequence": "first"
},
{
"ORCID": "http://orcid.org/0000-0001-9272-6906",
"affiliation": [],
"authenticated-orcid": false,
"family": "Matetic",
"given": "Andrija",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-7003-8192",
"affiliation": [],
"authenticated-orcid": false,
"family": "Domjanović",
"given": "Josipa",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Kljaković-Gašpić",
"given": "Toni",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-5621-580X",
"affiliation": [],
"authenticated-orcid": false,
"family": "Šarić",
"given": "Lenko",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Ilić",
"given": "Darko",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Došenović",
"given": "Svjetlana",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Domazet",
"given": "Josipa",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Kovač",
"given": "Ruben",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Runjić",
"given": "Frane",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Stipić",
"given": "Sanda Stojanović",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Duplančić",
"given": "Božidar",
"sequence": "additional"
}
],
"container-title": "Microorganisms",
"container-title-short": "Microorganisms",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2022,
5,
30
]
],
"date-time": "2022-05-30T03:43:03Z",
"timestamp": 1653882183000
},
"deposited": {
"date-parts": [
[
2022,
5,
30
]
],
"date-time": "2022-05-30T04:00:51Z",
"timestamp": 1653883251000
},
"indexed": {
"date-parts": [
[
2022,
5,
30
]
],
"date-time": "2022-05-30T04:42:53Z",
"timestamp": 1653885773518
},
"is-referenced-by-count": 0,
"issue": "6",
"issued": {
"date-parts": [
[
2022,
5,
28
]
]
},
"journal-issue": {
"issue": "6",
"published-online": {
"date-parts": [
[
2022,
6
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://creativecommons.org/licenses/by/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
5,
28
]
],
"date-time": "2022-05-28T00:00:00Z",
"timestamp": 1653696000000
}
}
],
"link": [
{
"URL": "https://www.mdpi.com/2076-2607/10/6/1118/pdf",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "1968",
"original-title": [],
"page": "1118",
"prefix": "10.3390",
"published": {
"date-parts": [
[
2022,
5,
28
]
]
},
"published-online": {
"date-parts": [
[
2022,
5,
28
]
]
},
"publisher": "MDPI AG",
"reference": [
{
"DOI": "10.1001/jama.2020.2648",
"doi-asserted-by": "publisher",
"key": "ref1"
},
{
"key": "ref2"
},
{
"DOI": "10.3390/antibiotics10050545",
"doi-asserted-by": "publisher",
"key": "ref3"
},
{
"DOI": "10.1097/CCM.0b013e3182281f33",
"doi-asserted-by": "publisher",
"key": "ref4"
},
{
"DOI": "10.1097/MCC.0000000000000908",
"doi-asserted-by": "publisher",
"key": "ref5"
},
{
"DOI": "10.1080/17476348.2017.1359090",
"doi-asserted-by": "publisher",
"key": "ref6"
},
{
"DOI": "10.1007/s40261-019-00861-x",
"doi-asserted-by": "publisher",
"key": "ref7"
},
{
"article-title": "Evaluation of the Effect of Nebulized N-Acetylcysteine on Respiratory Secretions in Mechanically Ventilated Patients: Randomized Clinical Trial",
"author": "Masoompour",
"first-page": "309",
"journal-title": "Iran. J. Med. Sci.",
"key": "ref8",
"volume": "40",
"year": "2015"
},
{
"DOI": "10.1002/14651858.CD001506.pub4",
"doi-asserted-by": "publisher",
"key": "ref9"
},
{
"article-title": "Acute Respiratory Distress Syndrome: The Berlin Definition",
"author": "Ranieri",
"first-page": "2526",
"journal-title": "JAMA",
"key": "ref10",
"volume": "307",
"year": "2012"
},
{
"DOI": "10.1186/s13054-021-03460-5",
"doi-asserted-by": "publisher",
"key": "ref11"
},
{
"article-title": "Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic Fibrosis",
"author": "Bennett",
"first-page": "S186",
"journal-title": "Ann. Am. Thorac. Soc.",
"key": "ref12",
"volume": "13",
"year": "2016"
},
{
"DOI": "10.1056/NEJMoa043891",
"doi-asserted-by": "publisher",
"key": "ref13"
},
{
"DOI": "10.1136/thx.52.10.900",
"doi-asserted-by": "publisher",
"key": "ref14"
},
{
"DOI": "10.1164/ajrccm.156.1.9512074",
"doi-asserted-by": "publisher",
"key": "ref15"
},
{
"DOI": "10.1172/JCI119138",
"doi-asserted-by": "publisher",
"key": "ref16"
},
{
"DOI": "10.4049/jimmunol.0803959",
"doi-asserted-by": "publisher",
"key": "ref17"
},
{
"DOI": "10.1371/journal.pone.0090164",
"doi-asserted-by": "publisher",
"key": "ref18"
},
{
"DOI": "10.1177/1753466619866102",
"doi-asserted-by": "publisher",
"key": "ref19"
},
{
"DOI": "10.1136/thoraxjnl-2014-205953",
"doi-asserted-by": "publisher",
"key": "ref20"
},
{
"article-title": "Mucoactive agents for airway mucus hypersecretory diseases",
"author": "Rogers",
"first-page": "1176",
"journal-title": "Respir. Care",
"key": "ref21",
"volume": "52",
"year": "2007"
},
{
"DOI": "10.1152/ajplung.00180.2010",
"doi-asserted-by": "publisher",
"key": "ref22"
},
{
"DOI": "10.29328/journal.jcicm.1001029",
"doi-asserted-by": "publisher",
"key": "ref23"
},
{
"DOI": "10.1186/s13054-021-03517-5",
"doi-asserted-by": "publisher",
"key": "ref24"
},
{
"DOI": "10.1186/s13613-020-00775-4",
"doi-asserted-by": "publisher",
"key": "ref25"
},
{
"DOI": "10.1007/s00134-020-06323-9",
"doi-asserted-by": "publisher",
"key": "ref26"
},
{
"DOI": "10.1371/journal.pone.0246318",
"doi-asserted-by": "publisher",
"key": "ref27"
},
{
"DOI": "10.1186/s13054-021-03571-z",
"doi-asserted-by": "publisher",
"key": "ref28"
},
{
"DOI": "10.1007/s00134-020-06062-x",
"doi-asserted-by": "publisher",
"key": "ref29"
},
{
"DOI": "10.1016/j.jiac.2021.01.011",
"doi-asserted-by": "publisher",
"key": "ref30"
},
{
"DOI": "10.3390/jcm10040555",
"doi-asserted-by": "publisher",
"key": "ref31"
},
{
"DOI": "10.3390/v9030058",
"doi-asserted-by": "publisher",
"key": "ref32"
},
{
"DOI": "10.1038/nrmicro3231",
"doi-asserted-by": "publisher",
"key": "ref33"
},
{
"DOI": "10.1016/j.mib.2016.11.003",
"doi-asserted-by": "publisher",
"key": "ref34"
},
{
"DOI": "10.1016/S2666-5247(20)30009-4",
"doi-asserted-by": "publisher",
"key": "ref35"
},
{
"DOI": "10.1093/cid/ciaa530",
"doi-asserted-by": "publisher",
"key": "ref36"
},
{
"DOI": "10.1002/14651858.CD006458.pub3",
"doi-asserted-by": "publisher",
"key": "ref37"
},
{
"article-title": "ffect of N-acetylcysteine inhalation on ventilator-associated pneumonia caused by biofilm in endotracheal tubes",
"author": "Qu",
"first-page": "278",
"journal-title": "Zhonghua Er Ke Za Zhi",
"key": "ref38",
"volume": "54",
"year": "2016"
},
{
"DOI": "10.1001/jama.2018.0949",
"doi-asserted-by": "publisher",
"key": "ref39"
},
{
"DOI": "10.1152/ajplung.00143.2012",
"doi-asserted-by": "publisher",
"key": "ref40"
},
{
"DOI": "10.1089/jamp.2015.1228",
"doi-asserted-by": "publisher",
"key": "ref41"
},
{
"DOI": "10.1186/s13054-021-03493-w",
"doi-asserted-by": "publisher",
"key": "ref42"
},
{
"DOI": "10.3390/antibiotics10080988",
"doi-asserted-by": "publisher",
"key": "ref43"
},
{
"DOI": "10.1164/rccm.202106-1354OC",
"doi-asserted-by": "publisher",
"key": "ref44"
}
],
"reference-count": 44,
"references-count": 44,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.mdpi.com/2076-2607/10/6/1118"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Virology",
"Microbiology (medical)",
"Microbiology"
],
"subtitle": [],
"title": "Effects of Different Inhalation Therapy on Ventilator-Associated Pneumonia in Ventilated COVID-19 Patients: A Randomized Controlled Trial",
"type": "journal-article",
"volume": "10"
}
